radionuclide therapy is that radioactivity doses are delivered in the tumor very accurately. During this treatment, a radiopharmaceutical is administered to the cancer patient. This radiopharmaceutical is combining a radionuclide and a tumor-targeting vector, that selectively binds to a target protein aberrantly upregulated at the surface of the cancer cells. Emissions of beta and/or alpha particles by the radionuclide cause lethal damage to tumor cells. Prior to the treatment, a diagnostic scan is made to assess the localization of the tumor lesions, as well as proper staging and stratification of the patients that can undergo radionuclide therapy. Currently, the diagnostic imaging drug is chemically different from the therapeutic, which can lead to inadequate treatment. Differences between these diagnostic and therapeutic drugs are eliminated by developing theranostic twins. Molecular twins are chemically identical, and therefore they have identical in vivo behavior and can serve for both imaging and therapy. In fact, the molecular twins contain the diagnostic and the therapeutic nuclide, and depending on the application one nuclide is radioactive, whereas the other one is still present but under its non-radioactive form. This innovative approach is based on easily available fluorine-18 for PET-diagnostics combined with b- or a-emitters for therapy. With these twins the right cancer patients are selected for treatment with optimal therapy. In this project funded by NWO-TTW, UMCG and Erasmus MC will develop theranostic twins for treating cancer. The best twin will be prepared for a first-in-man clinical trial.
A healthy population and excellence in healthcare through research and education. This is what Erasmus MC stands for. Conducting groundbreaking work, pushing boundaries and leading the way in research, education, and healthcare. We are practical people with a high level of expertise, working hard to improve and renew the healthcare of today and the public health of tomorrow.
The candidate will be positioned at the department of Radiology and Nuclear Medicine. Our department is known for its forefront research and its state-of-the-art facilities. The concept of peptide receptor radionuclide therapy (PRRT) was introduced in our department and several theranostic agents were developed and tested from bench-to-bedside. The candidate will be a member of the RadioPharmaceutical Chemistry group and will work in collaboration with other research groups specialized in molecular imaging and targeted radiotherapy.
Applications are invited from enthusiastic and talented young researchers with an active interest in tracer development and translational radiopharmaceutical research. Qualifications and skills:
These criteria are considered advantages, but not requirements:
Before you apply please check our conditions for employment.
For more information about this position, please contact Dr. Yann Seimbille, 010 703 89 61.
If you are excited by the thought of this position and would like to apply, please do so by using the application form on our website.
No agencies please.
Did we get you excited about this position? Submit your application through the application button. You will receive a confirmation of receipt from our recruiter right away.
Based on your application, we check to see if there is a fit between us. We will let you know as soon as possible whether you are invited for an interview.
You have been invited for an interview, great! In this first meeting we get to know each other and see if You can form an idea of the position, the department and Erasmus MC. If the interview goes well usually a second interview follows.
It’s a match! Your future manager will discuss your salary and employment with you. You will also receive more information about our other terms of employment.
Your first working day has come! We are more than happy to have you. Your new department will give you a warm welcome and provide you with all the information you need. Enjoy your job at Erasmus MC!
Erasmus MC is an international leading academic hospital in Rotterdam. We are recognized as a world-class scientific research organization aiming to improve our understanding of diseases and disorders and helps to predict, treat and prevent them. We have access to the latest equipment and techniques. A working environment that gets the best out of people.
Find out more about Erasmus MC